OUR Supervisory BOARD

The evorion supervisory board is formed by a group of international experts and forward-thinking leaders of the healthcare industry who bring comprehensive business expertise from different market segments and will work closely with our management team to guide go-to-market and commercial strategies, as well as shape continued innovation of our products.

scroll-button

the Supervisory bOARD

Dr. Helge Lubenow

CEO – Proteomedix AG

Dr. Helge Lubenow is a senior management leader with extensive experience in molecular diagnostics, personalized medicine, and clinical research. She held various top-management positions at QIAGEN, Germany for 18 years where she led oversees business development and successfully managed R&D operational restructuring and integration globally.

Dr. Oliver Schacht

President & CEO – OpGen Inc.

Dr. Oliver Schacht is a senior corporate finance executive and an expert in the molecular diagnostic industry. He has extensive experience in developing and implementing commercial strategies, and financial measures globally during his tenure at Epigenomics AG, Germany, and Epigenomics Inc., USA. He also held various executive management positions at Germany’s biotechnology industry association BIO Deutschland e.V.

Steffen Bersch

CEO – SSI SCHÄFER Group

Mr. Steffen Bersch is an international senior executive with global expertise in several management positions for advanced technologies in the food, healthcare, and power sector for more than 15 years. He is a leader in business operations and go-to-market strategies. Among other responsibilities at GEA Group AG, he led the GEA Middle East as managing director in Dubai and accelerated business trajectory.

Christian Scheiner

CEO – Cilian AG

Mr. Christian Scheiner is a senior business executive who has expertise in the pharmaceutical industry for more than three decades. He spearheaded trans-Atlantic (Europe and North America) operational and strategic business in several research-based pharmaceutical and biotech companies (Boehringer-Ingelheim), generics manufacturers (STADA Arzneimittel AG), life science companies (VITA 34 International AG).